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Introduction
Pulmonary embolism (PE) is a common cardiovascular disease
with high mortality. Among the cardiovascular diseases, it
represents the third cause of death after acute myocardial
infarction and stroke.1–4 Despite the ongoing progress in
diagnosis, treatment, and prevention over the last two dec-
ades, thenumberofdeathsstill remainshigh,5,6 representing9
to 11% of cases of PE in thefirst 30 days after the acute event.7
The development of predictive models to define the risk of
earlymortality and the validation of thesemodels are the goals
tobeachieved tooptimize themanagementofpatientswithPE.
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Abstract Background Acute pulmonary embolism (PE) is burdened by high mortality, espe-
cially within 30 days from the diagnosis. The development and the validation of
predictive models for the risk of early mortality allow to differentiate patients who can
undergo home treatment from those who need admission into intensive care units.
Methods To validate the prognostic model for early mortality after PE diagnosis
proposed by the European Society of Cardiology (ESC) in 2014, we analyzed data of a
cohort of 272 consecutive patients with acute PE, observed in our hospital during a
10-year period. Moreover, we evaluated the additional contribution of D-dimer,
measured at PE diagnosis, in improving the prognostic ability of the model. All cases
of PE were objectively diagnosed by angiography chest CT scan or perfusion lung scan.
Results The overall mortality rate within 30 days from PE diagnosis was 10% (95%
confidence interval [CI]: 6.4–13.5%). According to the ESC prognostic model, the risk of
death increased 3.23 times in the intermediate-low-risk category, 5.55 times in the
intermediate-high-risk category, and 23.78 times in the high-risk category, as com-
pared with the low-risk category. The receiver operating characteristic analysis showed
a good discriminatory power of themodel (area under the curve [AUC] ¼ 0.77 [95% CI:
0.67–0.87]), which further increased when D-dimer was added (AUC ¼ 0.85 [95% CI:
0.73–0.96]).
Conclusion This study represents a good validation of the ESC predictive model
whose performance can be further improved by adding D-dimer plasma levels
measured at PE diagnosis.
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In 2014, the European Society of Cardiology (ESC) proposed
a prognostic model for early mortality (i.e., within 30 days)
after PE diagnosis based on integrated clinical, laboratory, and
instrumental parameters,7 which identifies four categories of
early mortality risk: high, intermediate-high, intermediate-
low, and low risk.8,9 The definition of risk category is based on
hemodynamic instability, class of Pulmonary EmbolismSever-
ity Index (PESI), evidence of right ventricle dysfunction (docu-
mented by echocardiography or computed tomography [CT]
angiography), and elevated cardiac biomarker levels, that is,
troponins or pro-brain natriuretic peptide (proBNP). This
model allows to differentiate patients who can undergo
home treatment (low-risk category), reducing hospital costs,
from thosewho need admission into intensive care units from
the early stages of the acute event (high-risk category).10,11
However, according toa recent study inwhich the abilityof the
2014 ESCmodel to predict 30-daymortality was assessed, the
risk stratification in patients at intermediate risk requires
further improvement.8
D-dimer is a product of fibrin degradation and increases in
the acute phase of venous thrombosis. The measurement of
plasma D-dimer has a clear diagnostic role in symptomatic
outpatients with suspected PE because of its high negative
predictive value.12Moreover,when anticoagulation is stopped
after the conventional treatment of a first episode of venous
thromboembolism,highD-dimer levelshavebeen showntobe
a risk factor for a thrombotic recurrence.13 Finally, the role of
D-dimer as a predictive prognostic biomarker for mortality
after PE diagnosis has been well demonstrated.14–16
The aim of this cohort study was to validate the predictive
model for earlymortality after acute PE diagnosis proposed by
the 2014 ESC guidelines in a cohort of patients with acute PE
recruited in the emergencydepartmentofour hospital in a 10-
year period. A secondary objective of the study was to assess
the additional contribution of the D-dimer, measured at PE
diagnosis, in improving the prognostic ability of the model.
Patients and Methods
Study Population and Diagnostic Tests
Weincluded in thecohort 272patientswith acutePE (117men
and 155 women, median age: 65 years [min–max: 24–92
years]) who attended the emergency department of theOspe-
dale Maggiore Policlinico, University of Milan, in the period
between January 2005 and May 2015. All cases of PE were
objectively diagnosed by angiography chest CT scan or perfu-
sion lung scan. We excluded patients younger than 18 years,
patients who refused to give their consent to the collection of
their data, and patients lacking of information on 30-day
follow-up. For every patient included in the study, a thorough
medical history was available as well as a careful physical
examination and diagnostic tests.
Concerning medical history, the risk factors for venous
thromboembolism were considered, in particular previous
episodes of venous thromboembolism, thrombophilia, recent
surgery, plaster casts, prolonged immobilization, estrogen
therapy, pregnancy, postpartum period, malignancy, obesity,
and chronic heart failure. Symptoms at presentation were
accurately analyzed, including dyspnea, syncope, shock,
hemoptysis, alteredmental status, phlebitic pain, and pleuritic
or substernal chest pain. We also analyzed vital signs (systolic
anddiastolicbloodpressure, heart rate, respiratory rate, oxygen
saturation on room air, and body temperature) and physical
signs (cyanosis, signs of deep vein thrombosis (DVT) in a limb,
and jugular turgor). Additional diagnostic tests were arterial
blood gas analysis, chest X-ray, electrocardiography, echocar-
diography, and laboratory parameters (D-dimer, troponin I,
proBNP, and lactate dehydrogenase). In particular, an immu-
noturbidimetric method (D-Dimer HS kit; Instrumentation
Laboratory, Bedford, Massachusetts, United States) was used
for the quantitative determination of D-dimer in human-
citrated plasma (blood collected into vacuum tubes containing
3.2% sodium citrate), following manufacturer’s instructions.
Lower limb ultrasonography was also performed to search
for DVT as a cause of PE.
Stratification of Early Mortality Risk
The clinical records of the patients were retrospectively
analyzed according to the 2014 ESC guidelines. The diagnos-
tic algorithm for risk stratification of early mortality after
acute PE diagnosis, proposed by the ESC in 2014, is reported
in ►Table 1.
For the definition of risk stratification, clinical para-
meters, PESI score, serum cardiac damage indices, and echo-
cardiography were taken into consideration. PESI score was
calculated for each patient, considering 11 clinical para-
meters detectable at the first visit to the emergency depart-
ment: age, sex, presence of cancer, heart failure, chronic lung
disease, heart rate above 110 beats perminute, systolic blood
pressure less than 100 mm Hg, respiratory rate greater than
Table 1 Stratification algorithm for early mortality in patients with acute pulmonary embolism
Early mortality
(at 30 d) risk classes
Risk parameters and scores
Shock or
hypotension
PESI class III–V
or sPESI  I
Signs of RV dysfunction
on an imaging test
Cardiac laboratory
biomarkers
High þ þ þ þ
Intermediate Intermediate-high  þ Both positive
Intermediate-low  þ Either one (or none) positive
Low   Assessment optional; if assessed both negative
Abbreviations: sPESI, simplified Pulmonary Embolism Severity Index; RV, right ventricle.
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30 breaths per minute, altered mental status, body tempera-
ture less than 36°C, and arterial oxygen saturation below
90%. The model assigns points for each applicable character-
istic, and calculates a total score by summing these points
and adding the patient’s age in years. Serological markers,
such as cardiac troponin I and proBNP, were measured at
patient arrival and 6 and 12 hours later. Bedside echocardio-
graphy was performed to find out right ventricular overload
signs and to estimate pulmonary pressure.
All these parameters allowed the definition of risk stra-
tification, dividing patients into four classes:
1. High-risk class: patients with shock or hemodynamic
instability.
2. Intermediate-high-risk class: patients without shock or
hemodynamic instability and with PESI greater than II,
echocardiographic or tomographic signs of right ventri-
cular overload in addition to altered serum markers of
cardiac damage and cardiac dysfunction.
3. Intermediate-low-risk class: patients without shock or
hemodynamic instability and with PESI greater than II
and either alteration of cardiac serummarkers (troponin I
and/or proBNP) or echocardiographic or tomographic
signs of right ventricular overload.
4. Low-risk class: patients with PESI scores I and II.
Anticoagulant therapy was set up in the whole cohort by
administration of unfractionated heparin or low-molecular-
weight heparin. Hemodynamically unstable patients were
treated with thrombolysis.
From the time of PE diagnosis, patients were followed up
for a period of 30 days. The study outcome was death within
30 days, whichwas confirmed throughmedical charts or (for
patients with early hospital discharge) via a telephone call
with their family members or through municipality charts.
The study was conducted following the ethical principles
of the Declaration of Helsinki, regulatory requirements, and
the code of Good Clinical Practice. The patients or their
relatives gave their written informed consent to the collec-
tion of their data for scientific purposes.
Statistical Analysis
All statistical analyses were performed using the statistical
packages SPSS, release 24.0 (IBM SPSS Inc., Chicago, Illinois,
United States), andR, release 3.0.0 (R Foundation for Statistical
Computing, Vienna, Austria). Continuous variables are pre-
sented as mean (standard deviation) or median (interquartile
range [IQR]), andcategoricalvariablesascountandpercentage.
The nonparametric Kruskal–Wallis test was used for compar-
ison of continuous variables between more than two groups.
The prognostic algorithm of earlymortality after PE diagnosis,
according to the 2014 ESC guidelines, has been validated by
means of a logistic regression model, with 30-day mortality
(0 ¼ no, 1 ¼ yes) as outcome and the four ESC risk categories
(low, intermediate-low, intermediate-high, and high), age
(continuous), and sex (0 ¼ female, 1 ¼ male) as predictors.
Age- and sex-adjusted odds ratios with 95% confidence inter-
vals (CI)were calculatedasestimatesof therelative riskofearly
mortality for all the four ESC risk categories, taking the lowest
one as reference. A receiver operating characteristic (ROC)
curvewas constructed and the areaunder the curve (AUC)was
calculated together with its 95% CI to determine the discrimi-
nating powerof theanalyzedmodel. To evaluate the additional
contribution of D-dimer in the prediction of early mortality
after PE diagnosis, a second logistic model was built, which
contained D-dimer (categorized at the 75th percentile of its
distribution in the whole cohort of patients with acute PE)
besides ESC risk categories, age, and sex. The AUC of the ROC
curve of this second model was calculated together with its
95% CI. A bootstrap analysis (200 replicates) was performed to
correct for optimism. Calibrationof the predictedprobabilities
was assessed by means of graphical methods, plotting them
against observed probabilities.
Results
Of the 272 patients with objectively confirmed acute PE
evaluated at the emergency department of our hospital
between 2005 and 2015, twenty-seven died within 30 days,
for a death rate of 10.0% (95% CI: 6.4–13.5%). In particular, 21
patients died because of PEwithin 3 days from the acute event
andtheother6patientsdiedwithin30days forheart failure (3),
major bleeding (1), embolic recurrence (1), andpneumonia (1).
All study subjects were white Caucasians. Baseline character-
istics of the whole cohort, divided according to survival status,
are shown in►Table 2. Shock, tachypnea, hemoptysis, andDVT
signs were more frequent in nonsurvivors (33.3, 63.0, 7.4, and
40.7%, respectively) than in survivors (6.9, 14.3, 2.0, and 26.5%,
respectively). Also neoplasia, heart failure, and immobilization
were more frequent in nonsurvivors (44.4, 7.4, and 37.0%,
respectively) than in survivors (20.4, 3.3, and 19.2%, respec-
tively). Nonsurvivors had also lower levels of systolic blood
pressure, pH, PaO2, and oxygen saturation, as well as higher
heart rate and respiratory rate, than survivors.
PE patients were evaluated according to the algorithm
proposed by the 2014 ESC guidelines for definition of a risk
class. Thirty-eight patients, all in the group of survivors, were
not considered in the analysis of the predictive model
because they lacked one or more parameters for the defini-
tion of the risk class. The remaining 234 patients (86% of the
whole cohort) have been divided into the four ESC classes
of risk (►Table 3). The mortality was 2.5% (2/81) in the low-
risk class, 9.5% (7/74) in the intermediate-low-risk class,
14.8% (8/54) in the intermediate-high-risk class, and 40%
(10/25) in the high-risk class. The difference in mortality
between intermediate-low- and intermediate-high-risk
class was 5.3% (95% CI: 6.3% to 16.9%). The risk of death
within 30 days increased progressively with the risk class,
being approximately 24-fold higher in the high-risk than
in the low-risk class (adjusted odds ratio: 23.78 [95% CI:
4.62–122.0]; ►Table 4). Plasma levels of D-dimer in the four
ESC risk classes are shown in ►Fig. 1. Median (IQR)
levels were 1447 ng/mL (633–3367) in the low-risk class,
2,520 ng/mL (900–5,800) in the low–intermediate-risk
class, 3,400 ng/mL (886–5,470) in the high-intermediate-
risk class, and 6,972 ng/mL (3,575–9,480) in the high-risk
class (Kruskal–Wallis test: p ¼ 0.001).
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To estimate the predictive capability of the model, a ROC
analysiswas conducted. The AUC of the predictivemodelwas
0.77 (95% CI: 0.67–0.87), indicating a good discriminative
power. The AUC further increased to 0.85 (95% CI: 0.73–0.96)
when D-dimer, categorized at the 75th percentile of its
distribution in the whole cohort (i.e., 5,000 ng/mL), was
added to a second predictive model together with ESC risk
classes, age, and sex. The ROC curves of the two predictive
models are shown in ►Fig. 2. After bootstrap analysis
(200 replicates), the AUC became 0.74 for the model without
D-dimer and 0.80 for the model with D-dimer. The calibra-
tion plot sorted from the model containing also D-dimer
levels, which compares the absolute probabilities of
observed deaths within 30 days with those predicted by
the model, is shown in►Fig. 3. The actual curve is very close
to the theoretical ideal situation (perfect coincidence
between observed and predicted probabilities) especially
for low probabilities, indicating a good predictive perfor-
mance of the model. The bias-corrected slope of the curve
was equal to 0.79 (ideal slope: 1.00).
The capability of D-dimer to better discriminate low- and
intermediate-low-risk patients has also been evaluated by
comparing mortality with D-dimer levels. In particular, out
of the 81 patients in the low ESC risk class, 64 had D-dimer
below 5,000 ng/mL and 17 had D-dimer 5,000 ng/mL.
One patient in each subgroup died within 30 days, for a
mortality of 1.6% in the low-risk class with D-dimer less than
5,000 ng/mL and 5.9% in the low-risk class with D-dimer
5,000 ng/mL. Considering the 74 patients in the intermedi-
ate-low ESC risk class, 45 had D-dimer below 5,000 ng/mL
(2 deaths) and 29 had D-dimer5,000 ng/mL (5 deaths), for a
mortality of 6.7% in the intermediate-low-risk class with
D-dimer less than 5,000 ng/mL and 13.8% in the intermedi-
ate-low-risk class with D-dimer 5,000 ng/mL.
Table 2 Baseline characteristics of the 272 patients with acute
pulmonary embolism divided according to the survival status at
30 days from the acute event
Features Survivors
n ¼ 245
Nonsurvivors
n ¼ 27
Sex (M/F) 102/143 15/12
Age 69.2 (15.5) 73.0 (13.5)
Neoplasia 50 (20.4) 12 (44.4)
Heart failure 8 (3.3) 2 (7.4)
Surgery (< 4 wk) 21 (8.6) 2 (7.4)
Fractures 20 (8.2) 4 (14.8)
Immobilization 47 (19.2) 10 (37.0)
Dyspnea 189 (77.1) 21 (77.8)
Tachypnea
(respiratory rate 30)
35 (14.3) 17 (63.0)
Chest pain 78 (32.0) 8 (30.0)
Syncope 76 (31.0) 9 (33.3)
Hemoptysis 5 (2.0) 2 (7.4)
DVT signs 65 (26.5) 11 (40.7)
Shock 17 (6.9) 9 (33.3)
Systolic blood pressure
(mm Hg)
129.4 (26.1) 120.2 (33)
Diastolic blood pressure
(mm Hg)
75.2 (15.5) 71.6 (17.9)
Heart rate (bpm) 95.2 (18.9) 101.7 (19.7)
Respiratory rate (bpm) 25.4 (6.6) 35 (8.8)
pH 7.5 (0.1) 7.3 (0.3)
PaO2 (mm Hg) 64.6 (17.7) 52 (9.4)
PaCO2 (mm Hg) 32.4 (7.1) 34 (15.6)
Sat O2 (%) 92 (5.6) 82 (12.2)
Abbreviation: DVT, deep vein thrombosis.
Note: Continuous variables are presented as mean (standard deviation)
and categorical variables as count (%).
Table 3 Risk class of early death (within 30 d after acute PE) calculated at PE diagnosis
Risk class of death
Low Intermediate-low Intermediate-high High Total
Survivors 79 (38%) 67 (32%) 46 (22%) 15 (7.2%) 207
Nonsurvivors 2 (7.4%) 7 (26%) 8 (30%) 10 (37%) 27
Abbreviation: PE, pulmonary embolism.
Notes: Data obtained from the 234 patients with acute PE (all the 27 nonsurvivors and 207 of the survivors) for whom all parameters for a correct risk
classification were available. In each row, percentages are calculated on the total numbers of survivors and nonsurvivors.
Table 4 Risk of 30-d mortality after acute PE according to the
2014 ESC risk class
Risk class Patients, N (%) Adjusted odds
ratio (95% CI)a
Low 81 (35) 1 (reference)
Intermediate-low 74 (32) 3.23 (0.60–17.24)
Intermediate-high 54 (23) 5.55 (1.05–29.23)
High 25 (11) 23.78 (4.62–122.0)
Abbreviations: ESC, European Society of Cardiology; PE, pulmonary
embolism.
Notes: Data obtained from the 234 patients with acute PE (all the 27
nonsurvivors and 207 of the survivors) for whom all parameters for a
correct risk classification were available.
aOdds ratios adjusted for age and sex.
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Discussion
The prognosticmodel for early death after acute PE diagnosis
proposed by the ESC in 2014 was validated in our cohort of
patients. The 30-day risk of death increased 3.23 times in the
intermediate-low-risk category, 5.55 times in the intermedi-
ate-high-risk category, and 23.78 times in the high-risk
category, as compared with the low-risk category. According
to the ROC analysis, the predictive model containing the four
ESC risk classes, age, and sex showed a good discriminatory
power, which further increased when D-dimer was added to
the model. In this study, we observed an overall 10% death
rate within 30 days since PE diagnosis, which is in line with
other recent studies that showed a 30-day mortality rate
ranging from 9 to 12%.17–20 Concerning mortality divided by
the subgroups, we observed a highmortality in the high-risk
class (40%) and a low mortality in the low-risk class (2.5%),
whereas the difference (5.3%) in mortality between inter-
mediate-high-risk class and intermediate-low-risk class
remains quite uncertain due to a wide confidence interval,
in accordance with previous results.8
We did not observe a relevant difference neither in male/
female ratio nor in age between survivors and nonsurvivors.
One would expect a higher mortality in the elderly, as con-
sidered in the PESI score and observed by Geibel et al.21 In our
cohort, the similar age distribution in survivors and nonsurvi-
vors might be due to the narrow age range of our patients. In
our patients, the prevalence of heart failure, cancer, and
immobilization was higher in nonsurvivors than in survivors,
according to previous findings by Huang et al.17
The prevalence of dyspnea, chest pain, and syncope was
similar in nonsurvivors as compared with survivors, while
shock, tachypnea, hemoptysis, and DVT signs were more fre-
quent in nonsurvivors. Our data are in agreement with the
findings of Agrawal et al.22 Nonsurvivors had lower values of
systolic blood pressure and higher values of heart rate and
respiratory rate than survivors. Lower values of blood pressure
are frequently observed in PE patientswith earlymortality.17,22
According to ameta-analysis of eight studies on 2,354 patients,
sinus tachycardiawas found tobepredictiveof30-daymortality
for PE.23 Tachycardia and tachypnea are frequently described in
PE patients not surviving at 30 days.24,25 The evaluation of
respiratory exchanges showed hypoxemia and low oxygen
saturation in nonsurvivors, confirming a major impairment in
this group of patients as reported also in previous studies.22,25
Fig. 1 Plasma levels of D-dimer in the four ESC risk classes (low,
intermediate-low, intermediate-high, and high). Data are reported as
median values, interquartile ranges (boxes), and 2.5th and 97.5th
percentiles (whiskers).
Fig. 2 ROC curves of the two predictive models without (dashed line)
and with (continuous line) D-dimer, categorized at the 75th percentile
of its distribution in the cohort of PE patients (i.e., 5,000 ng/mL). The
two models also contained the four ESC risk classes, age, and sex.
Fig. 3 Calibration plot of the predictive model of death within 30 days
since the diagnosis of acute PE. The plot was obtained after 200
bootstrap replicates to correct for optimism. The dashed diagonal line
represents the ideal situation when predictive and observed prob-
abilities of the outcome exactly coincide (slope ¼ 1.00).
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Concerning the estimate of the predictive capability of the
2014 ESCmodel, our data confirm the efficacyof themodel in
stratifying the risk of mortality at 30 days, as recently
assessed by Becattini et al.8 Moreover, our data indicate
that it is possible to increase the predictive ability of the
model by adding D-dimermeasured at PE diagnosis, which is
an easy and cheap biomarker frequently evaluated in PE
patients. The role of D-dimer as a diagnostic tool in patients
with suspected PE and as a prognostic tool for VTE recur-
rence after anticoagulant therapy withdrawal is well recog-
nized,12,13 and previous studies have demonstrated its
predictive role for mortality after PE diagnosis.14–16 To the
best of our knowledge, the addition of D-dimer to
the predictive ESC model has been evaluated for the first
time in our study. By adding D-dimer to a predictive model
containing the four ESC risk classes, age, and sex gives the
possibility to reclassify some individuals as low risk for early
death, thus increasing the number of patients who can safely
be discharged from the hospital for home treatment.
Some limitations of our study should be considered. First,
the retrospective nature of the study limited the possibility
to retrieve in all PE patients the information on some
parameters for the correct definition of the ESC risk class
for early mortality. However, most of the patients (86%)
could be correctly classified and included in the prediction
model, and the 38 patients who could not be included (all
survivors) would be classified as intermediate-low- or low-
risk patients, thus minimizing the possibility of having
obtained biased results. Second, this is a single-center study,
and the results might not be necessarily applicable to PE
patients admitted to the emergency department of other
hospitals. Nonetheless, all patients in this study were con-
secutively admitted to the emergency department of a large
municipality hospital and covered a wide inclusion time-
frame in which very few has changed in the approach to the
patients, and the 10% rate of early death that we observed did
not differ from that of other studies, thus reducing the
possibility of a selection bias. Finally, all participants were
white Caucasians, potentially limiting the generalizability of
the study findings to other populations.
In conclusion, this study represents a good validation of the
predictive model for early mortality after acute PE diagnosis
proposed by the 2014 ESC guidelines. Adding D-dimer levels
measured at PE diagnosis could further improve the perfor-
mance of the prediction model, in particular, discriminating
the mortality in low-risk classes. This could allow to identify
patients who need hospitalization from those who can be
safely discharged. An external validation to other cohorts of
patients with acute PE is warranted to confirm our findings.
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